Description: <b>Celecoxib</b> inhibits the formation of prostaglandins: used primarily to treat pain and other symptoms of osteoarthritis, rheumatoid arthritis, joint and musculoskeletal conditions.<br>
<p><b>Celecoxib</b> is a diaryl-substituted selective cyclooxygenase-2 inhibitor that lowers prostaglandin synthesis and is used clinically as an oral nonsteroidal anti-inflammatory drug. It is formally classified as a small-molecule NSAID and COX-2–preferential inhibitor. Standard abbreviations include celecoxib and CEL. In oncology, its main rationale is suppression of the COX-2/PGE2 inflammatory-tumor axis, with additional COX-2-independent effects reported at higher experimental concentrations, including interference with PDK1/Akt signaling, ER calcium handling, and stress-linked apoptosis pathways. Nestronics lists it as an NSAID and currently indexes mainly EMT, HIF-1α/VEGF, COX-2, NF-κB, p65, and TGF-β/SMAD3-related findings.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>COX-2 inhibition with reduced PGE2 signaling and downstream inflammatory, proliferative, angiogenic, and immune-evasive tumor support</li>
<li>Suppression of NF-κB-linked inflammatory survival programs</li>
<li>Reduction of hypoxia/angiogenesis signaling including HIF-1α and VEGF in relevant models</li>
<li>Partial inhibition of PDK1/Akt survival signaling in some tumor systems</li>
<li>COX-2-independent ER stress and Ca²⁺ dysregulation via SERCA-related effects at supratherapeutic or high in-vitro concentrations</li>
<li>Contextual chemosensitization, including effects on apoptosis threshold and in some reports drug-resistance programs such as P-gp</li>
<li>Possible ancillary carbonic anhydrase inhibition is mechanistically interesting but not established as the dominant clinical anticancer mechanism</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Celecoxib is orally active. Peak plasma levels occur at about 3 hours, effective half-life is about 11 hours, steady state is reached by about day 5, and the drug is highly protein bound. Exposure is roughly dose-proportional up to 200 mg twice daily, with less-than-proportional increases above that range because of solubility limits. It is metabolized mainly by CYP2C9, so poor metabolizers and strong CYP2C9 interactions are clinically relevant.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> This is an important translation constraint. Many direct pro-apoptotic, SERCA/ER-stress, and stronger Akt-related anticancer effects are reported in vitro at concentrations commonly above those readily achievable with standard anti-inflammatory dosing. By contrast, COX-2/PGE2 suppression is clearly clinically reachable and is the most exposure-plausible core mechanism. Therefore, low- to mid-micromolar inflammatory and microenvironment effects are more translatable than high-concentration cytotoxic claims.</p>
<p><b>Clinical evidence status:</b> Strong clinical deployment exists for pain/inflammatory indications, not for cancer treatment. In oncology, evidence is mixed: extensive preclinical support, some small human and adjunct studies, but major randomized adjuvant trials in unselected breast and stage III colon cancer were negative overall. A more recent biomarker-defined signal has emerged in PIK3CA-activated stage III colon cancer, where celecoxib appeared beneficial in subgroup analysis, so any cancer role currently looks biomarker- and context-dependent rather than broadly established.</p>
<h3>Mechanistic table</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>COX-2 / PGE2 inflammatory signaling</td>
<td>COX-2 activity ↓; PGE2 tone ↓; proliferation, survival, invasion, immune evasion ↓</td>
<td>Inflammatory prostaglandin signaling ↓</td>
<td>R/G</td>
<td>Core anti-inflammatory antitumor mechanism</td>
<td>Best-supported and most clinically reachable mechanism; strongest translational anchor for oncology repurposing</td>
</tr>
<tr>
<td>2</td>
<td>NF-κB inflammatory survival axis</td>
<td>NF-κB/p65 ↓; inflammatory survival transcription ↓</td>
<td>Inflammatory signaling ↓</td>
<td>R/G</td>
<td>Reduced survival and inflammatory tone</td>
<td>Consistent with Nestronics and broader literature; partly downstream of reduced PGE2 but may also reflect parallel signaling effects</td>
</tr>
<tr>
<td>3</td>
<td>HIF-1α / VEGF angiogenesis axis</td>
<td>HIF-1α ↓; VEGF ↓; angiogenic support ↓</td>
<td>↔ or angiogenic signaling ↓ in inflammatory settings</td>
<td>G</td>
<td>Antiangiogenic pressure</td>
<td>Likely relevant in hypoxic and COX-2-high tumors; fits both Nestronics indexing and broader COX-2/PGE2 biology</td>
</tr>
<tr>
<td>4</td>
<td>TGF-β / SMAD3 / EMT</td>
<td>TGF-β ↓; SMAD3 ↓; EMT ↓; migration/invasion ↓</td>
<td>↔</td>
<td>G</td>
<td>Anti-migratory and anti-invasive effect</td>
<td>Nestronics support is specific here; likely more tumor-contextual than universally dominant</td>
</tr>
<tr>
<td>5</td>
<td>PDK1 / Akt survival signaling</td>
<td>PDK1/Akt ↓ (context-dependent); apoptosis threshold ↓</td>
<td>↔</td>
<td>R/G</td>
<td>COX-independent survival suppression</td>
<td>Mechanistically important in the celecoxib literature, but many strong effects are reported at higher in-vitro concentrations</td>
</tr>
<tr>
<td>6</td>
<td>Ca²⁺ homeostasis and ER stress</td>
<td>ER Ca²⁺ reuptake ↓; cytosolic Ca²⁺ stress ↑; ER stress/apoptosis ↑</td>
<td>Potential stress if exposure is high enough</td>
<td>P/R</td>
<td>Stress-triggered apoptosis</td>
<td>Usually linked to SERCA interference and considered mainly a high-concentration or COX-independent mechanism</td>
</tr>
<tr>
<td>7</td>
<td>Mitochondrial apoptosis program</td>
<td>Caspase activation ↑; Bcl-2-family survival balance shifts toward apoptosis</td>
<td>↔</td>
<td>R/G</td>
<td>Apoptotic execution</td>
<td>Generally downstream of Akt inhibition, ER stress, or combined treatment sensitization rather than the first initiating event</td>
</tr>
<tr>
<td>8</td>
<td>Chemosensitization</td>
<td>Drug sensitivity ↑; apoptosis with cytotoxics ↑</td>
<td>Potential inflammation/pain benefit in host context</td>
<td>G</td>
<td>Adjunctive therapy potential</td>
<td>Observed preclinically and in some clinical adjunct settings, but not confirmed as a broad survival-improving strategy in unselected populations</td>
</tr>
<tr>
<td>9</td>
<td>P-gp and resistance signaling</td>
<td>P-gp ↓ (model-dependent); intracellular drug retention ↑</td>
<td>↔</td>
<td>G</td>
<td>Possible reversal of drug resistance</td>
<td>Interesting but not core; should be treated as secondary and context-specific</td>
</tr>
<tr>
<td>10</td>
<td>Carbonic anhydrase inhibition</td>
<td>CA-related pH adaptation ↓ (context-dependent)</td>
<td>Off-target CA interaction possible</td>
<td>↔</td>
<td>Ancillary microenvironment effect</td>
<td>Celecoxib can inhibit carbonic anhydrases, but this is better viewed as a mechanistic side branch than the main oncology rationale for celecoxib itself</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Overall efficacy signal mixed; biomarker-defined benefit more plausible than broad use</td>
<td>Cardiovascular, renal, GI, and drug-interaction liabilities constrain chronic escalation</td>
<td>G</td>
<td>Limits generalized oncology deployment</td>
<td>Main constraint is that clinically achievable exposure strongly supports COX-2/PGE2 modulation, whereas many direct cytotoxic claims require higher concentrations; major adjuvant trials were negative overall, though PIK3CA-activated colon cancer is a notable exception signal</td>
</tr>
</table>
<p>P: 0–30 min</p>
<p>R: 30 min–3 hr</p>
<p>G: >3 hr</p>